Inside the Gulf biotech deal model, ahead of RGMBS 2026 in Riyadh

The Gulf is reshaping biotech deal-making around sovereign capital, guaranteed offtake and explicit localization mandates, creating a model distinct from Western venture-backed ecosystems. An analysis cited in region-wide commentary found Middle East and North Africa sovereign wealth funds hold the world’s largest concentration of sovereign-owned assets relative to GDP — “more than 1.4 times as of 2024, against roughly 0.1 times in Europe and Asia.” That patient, policy-aligned capital underpins major projects: JLL recorded close to 400 healthcare transactions in the GCC between 2021 and April 2025, with the UAE accounting for 198 deals and Saudi Arabia 170. Across three editions of the Riyadh Global Medical Biotechnology Summit (RGMBS) there have been 59 agreements, including 40 in 2024 with associated deal value above $100 million.

“Patient capital combined with policy alignment is a distinct proposition, not a regional variant of the venture-backed model,” the analysis states, summing up how sovereign balance sheets and government strategy change underwriting and partner selection.

How the Gulf model operates

The region’s strategic advantages are practical as well as financial. Global companies view the Gulf as a distribution and manufacturing hub between Europe, Asia and Africa: Novo Nordisk’s May 2026 announcement to build a regional distribution center in the UAE — one of three hubs worldwide intended to serve up to 70 countries and support treatment access for more than 2.6 million patients — exemplifies the logic. Saudi Arabia hosts Pfizer’s manufacturing facility at King Abdullah Economic City and has Ministry of Health agreements with Sanofi to localize insulin production with an explicit eye to exports to wider Middle East markets.

Deal structures routinely rely on guaranteed offtake. “When government commits to purchase a defined output volume, a manufacturing investment converts from a demand-risk bet into a capacity-delivery problem,” the report notes — a critical change for capital-intensive biologics and vaccine facilities. That promise is reinforced by incentives and institutional supports:

• Tax credits of up to 50% on Saudi worker payroll and training for ten years;
• Salary support through the Human Resources Development Fund;
• Special economic zones offering tax reductions and eased foreign talent rules;
• Non-dilutive grants such as the Saudi Innovation Grants Program (launched December 2024);
• Regulatory clarity from the Saudi Food and Drug Authority, benchmarked at WHO Maturity Level 4 and offering frameworks for advanced therapy medicinal products.

Deal flow, players and structures

Sovereign and state-backed vehicles are primary deployers of capital. Lifera, a contract development and manufacturing organization wholly owned by the Public Investment Fund and established in 2023, is highlighted as a direct industrial builder rather than a financial investor. Domestic venture activity is rising — Beta Lab reported more than 200 funding applications in a single year, many from international startups — while structured international entries include a $50 million fund launched by SBI Holdings with the Ministry of Investment, KAIMRC and BIM Ventures to channel capital into Japanese biotech startups at KAIMRC.

Institutional architecture is expanding to match capital and policy. The Riyadh Biocentral Foundation, approved under the Royal Commission for Riyadh City and chaired by the Crown Prince, is tasked with biotechnology zones, incubation and site infrastructure that would host international partners and local operators.

Outlook

Therapeutics and platform biotechnology in the Gulf remain earlier on the investment curve than clinics and hospitals, according to transaction breakdowns that show pharmaceuticals and biotechnology accounted for 25 and 15 transactions respectively within the JLL dataset. But the combination of sovereign balance sheets, guaranteed procurement, technology transfer frameworks and regulatory predictability creates a distinct pathway for capital-intensive manufacturing and localization. As RGMBS prepares for its 2026 summit in Riyadh, the deal record and policy scaffolding suggest the Kingdom and its Gulf neighbours will continue to attract multinational partners seeking capacity, market access and long-horizon investment structures that differ fundamentally from venture-led models.